Recent Curative Effect Observation of Sustained-release 5-Fluorouracil Used during Operation in Patients with Advanced Ovarian Elithelial Carcinoma

Jiang Yuan,Han Ke,Zhou Huaijun,Ling Jingxian,Zhou Bai,Li Rong,Weng Qiao

DOI: https://doi.org/10.3969/j.issn.1673-548X.2013.09.037

2013-01-01

Abstract:Objective To evaluate the efficacy and side effects of sustained-release 5-Fluorouracil used during operation in the treatment of advanced ovarian elithelial carcinoma.Methods Retrospective analysis was utilized to analyze 62 advanced ovarian cancer patients diagnosed definitely by pathology in the Nanjing Drum Tower Hospital from September 2006 to October 2011.The patients were divided into two groups.The group of sustained-release 5-fluorouracil used during operation combined with TP chemotherapy after operation was as research group,and the group of TP chemotherapy only after operation was as control group.Results As for the preoperative CA125 levels of the two groups,the difference was not statistically significant(P>0.05).After the first cycle chemotherapy,CA125 levels in reseach group were lower than those in control group(P<0.05),but there was no significant difference between two groups after second,third or fourth cycle chemotherapy(P>0.05).For first treatment ovarian cancer patients,CA125 levels in research group were lower than those in control group after first cycle(P<0.05).For the recurrent ovarian cance patients,CA125 levels in research group were lower than those in control group after first and second cycle( P<0. 05). Ascites effective rate was 68%,Pelvic mass effective rate was 47%Lymph node metastasis effective rate was 30% in the research group,but there was no significant differences between two groups in the toxicities of hypoleukemia,anemia,thrombocytopenia digestive disturbance,liver function damage,renal function damage,phalacrosis.Conclusion Intraoperative use of sustained- release 5- fluorouracil intraperitoneal chemotherapy is effective and feasible for the advanced ovarian cancer after optimally cytoreductive surgery in particular to recurrent ovarian cancer,and does not increase toxicity in patients,so it can be clinically acceptable.